ASH Annual Meeting | Conferences

December 15, 2021

Liso-cel was found to improve quality of life in patients with large B-cell lymphoma compared with standard of care.

December 15, 2021

Updated findings from the CARTITUDE-1 trial presented at the 2021 ASH Annual Meeting and Exposition show that the use of a CAR T-cell therapy resulted in durable responses that lasted at nearly 2 years of follow-up across most subgroups with relapsed/refractory multiple myeloma.

December 14, 2021

Acalabrutinib demonstrated a favorable risk-benefit profile in R/R CLL.

December 14, 2021

Compared with ibrutinib, acalabrutinib demonstrates less toxicity burden In CLL.

December 14, 2021

Magrolimab will be tested in combination with various antileukemia therapies at multiple disease points, such as the first line and remission stages.

December 14, 2021

Early study results indicate that YTB323 may be effective and safe for the treatment of patients with diffuse large B-cell lymphoma.

December 14, 2021

Venetoclax dosed at either 400 mg or 800 mg in combination with daratumumab and dexamethasone showed promising preliminary results in a phase 1/2 study.

December 14, 2021

In the MEDALIST analysis that was presented at the 2021 ASH Annual Meeting, investigators sought to further characterize the effects of luspatercept in patients with low-risk myelodysplastic syndrome.

December 14, 2021

Having knowledge that their multiple myeloma was incurable was associated with poor quality of life outcomes in patients.

December 14, 2021

The XVd regimen appears effective at prolonging progression-free survival with decreased toxicity when administered at lower doses of selinexor or the standard dose.